Clinical Trials For Supplement Claims Not An FTC Rule, But A Standard
This article was originally published in The Rose Sheet
Executive Summary
FTC Bureau of Consumer Protection official Richard Cleland takes on the hot-button issue by explaining that a supplement health or structure/function claim doesn't need support from research with the size and scope of studies looking at the safety and efficacy of a drug ingredient proposed for a certain indication. Supplement ad claims, though, still need competent and reliable scientific evidence as support.
You may also be interested in...
Algae Tab Marketer Energybits 'Misunderstands' Claims Substantiation – NARB
Energybits' position in a contentious National Advertising Division review and subsequent appeal suggests a failure to grasp marketers’ responsibilities when using health claims for food or dietary supplement products, according to a National Advertising Review Board panel. Energybits maintains the decisions amount to bullying of a small company with ample support for its claims.
Gerber-FTC Settlement Stipulates Clinical Trials For Infant Formula Claims
FTC filed its complaint in 2014 alleging Gerber, part of Nestlé Nutrition North America, deceptively advertised that feeding Good Start Gentle formula to infants with a family history of allergies prevents or reduces the risk that the infants will develop allergies.
FTC's Prevagen Complaint Revived: Court Says 'Deceptive' Ad Allegation Plausible
District court erred in dismissing FTC complaint that Prevagen marketer Quincy Biosciences used deceptive representations in ads, Second Circuit says in long-awaited order. FTC and New York attorney general, along with advocacy group TINA, criticize Quincy's post hoc data analyses finding "false positives."